Oppenheimer Asset Management’s AdaptHealth AHCO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$565K Sell
54,252
-16,711
-24% -$187K 0.01% 867
2026
Q1
$844K Buy
70,963
+1,602
+2% +$16.4K 0.01% 761
2025
Q4
$691K Sell
69,361
-3,509
-5% -$33.5K 0.01% 758
2025
Q3
$652K Buy
72,870
+36,201
+99% +$335K 0.01% 848
2025
Q2
$346K Buy
36,669
+3,872
+12% +$34.2K ﹤0.01% 955
2025
Q1
$356K Buy
32,797
+2,081
+7% +$20.9K ﹤0.01% 929
2024
Q4
$292K Buy
30,716
+2,902
+10% +$29.4K ﹤0.01% 988
2024
Q3
$312K Buy
27,814
+7,031
+34% +$74.7K ﹤0.01% 1001
2024
Q2
$208K Buy
20,783
+6,879
+49% +$69.9K ﹤0.01% 1072
2024
Q1
$160K Buy
13,904
+113
+0.8% +$960 ﹤0.01% 1047
2023
Q4
$101K Sell
13,791
-2,144
-13% -$16.9K ﹤0.01% 1134
2023
Q3
$145K Buy
15,935
+618
+4% +$7.41K ﹤0.01% 1101
2023
Q2
$186K Buy
+15,317
New +$171K ﹤0.01% 1070

Other funds holding AHCO

Oppenheimer Asset Management's AHCO Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its AdaptHealth (AHCO) stake by 24% in Q2 2026, selling an estimated $187K and leaving 54,252 shares worth $565K. The position accounts for 0.01% of the portfolio, ranked #867.

Oppenheimer Asset Management first reported a position in AHCO in Q2 2023 and has held it in 13 quarters since. The position peaked at $844K in Q1 2026. 239 funds tracked by Wall St. Rank hold AHCO as of Q2 2026.

  • Oppenheimer Asset Management held 54,252 shares of AdaptHealth worth $565K as of Q2 2026.
  • Oppenheimer Asset Management sold 16,711 AdaptHealth shares in Q2 2026, an estimated $187K.
  • AdaptHealth made up 0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #867 holding.
  • Oppenheimer Asset Management first reported a position in AdaptHealth in Q2 2023 and has held it in 13 quarters since.
  • Oppenheimer Asset Management's AdaptHealth position peaked at $844K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held AdaptHealth as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.